Cao P, Li G, Huang L, Zhao S, Hu Y, Qin L, et al. Screening of stabilizers for LC-MS/MS analysis of clevidipine and its primary metabolite in dog whole blood. Bioanalysis. 2015;7:1457-69 pubmed publisher

Raina S, Van Eerdenbrugh B, Alonzo D, Mo H, Zhang G, Gao Y, et al. Trends in the precipitation and crystallization behavior of supersaturated aqueous solutions of poorly water-soluble drugs assessed using synchrotron radiation. J Pharm Sci. 2015;104:1981-1992 pubmed publisher

Ye M, Tang L, Luo M, Zhou J, Guo B, Liu Y, et al. Size- and time-dependent alteration in metabolic activities of human hepatic cytochrome P450 isozymes by gold nanoparticles via microsomal coincubations. Nanoscale Res Lett. 2014;9:642 pubmed publisher

Hu L, Sun H, Zhao Q, Han N, Bai L, Wang Y, et al. Multilayer encapsulated mesoporous silica nanospheres as an oral sustained drug delivery system for the poorly water-soluble drug felodipine. Mater Sci Eng C Mater Biol Appl. 2015;47:313-24 pubmed publisher

Chattoraj S, Bhugra C, Li Z, Sun C. Effect of heating rate and kinetic model selection on activation energy of nonisothermal crystallization of amorphous felodipine. J Pharm Sci. 2014;103:3950-3957 pubmed publisher

Berthod L, Roberts G, Whitley D, Sharpe A, Mills G. A solid-phase extraction method for rapidly determining the adsorption coefficient of pharmaceuticals in sewage sludge. Water Res. 2014;67:292-8 pubmed publisher

Matsuda Y, Konno Y, Hashimoto T, Nagai M, Taguchi T, Satsukawa M, et al. Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats. Pharm Res. 2015;32:604-16 pubmed publisher

Yang Z, Nollenberger K, Albers J, Moffat J, Craig D, Qi S. The effect of processing on the surface physical stability of amorphous solid dispersions. Eur J Pharm Biopharm. 2014;88:897-908 pubmed publisher

Khodov I, Efimov S, Nikiforov M, Klochkov V, Georgi N. Inversion of population distribution of felodipine conformations at increased concentration in dimethyl sulfoxide is a prerequisite to crystal nucleation. J Pharm Sci. 2014;103:392-4 pubmed publisher

Sridhar V, Surya Sandeep M, Ravindra Babu P, Naveen Babu K. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using felodipine and hesperetin in combination in Wistar rats and everted rat gut sacs in vitro. Phytother Res. 2014;28:699-705 pubmed publisher

Huang Z, Bai S, Chen L, Wang J, Ding B. [Effect of puerarin combined with felodipine on mRNA and protein expression of apelin and APJ in renovascular hypertensive rat]. Zhongguo Zhong Yao Za Zhi. 2013;38:381-5 pubmed

Qi S, Moffat J, Yang Z. Early stage phase separation in pharmaceutical solid dispersion thin films under high humidity: improved spatial understanding using probe-based thermal and spectroscopic nanocharacterization methods. Mol Pharm. 2013;10:918-30 pubmed publisher

Solanko K, Surov A, Perlovich G, Bauer Brandl A, Bond A. Felodipine-diazabicyclo[2.2.2]octane-water (1/1/1). Acta Crystallogr C. 2012;68:o456-8 pubmed publisher

Zhang Y, Zhang X, Liu L, Wang Y, Tang X, Zanchetti A. Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial?. J Hypertens. 2012;30:2202-12 pubmed publisher

Papadimitriou S, Barmpalexis P, Karavas E, Bikiaris D. Optimizing the ability of PVP/PEG mixtures to be used as appropriate carriers for the preparation of drug solid dispersions by melt mixing technique using artificial neural networks: I. Eur J Pharm Biopharm. 2012;82:175-86 pubmed publisher

Dybdahl M, Nikolov N, Wedebye E, Jónsdóttir S, Niemelä J. QSAR model for human pregnane X receptor (PXR) binding: screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity. Toxicol Appl Pharmacol. 2012;262:301-9 pubmed publisher

Langham Z, Booth J, Hughes L, Reynolds G, Wren S. Mechanistic insights into the dissolution of spray-dried amorphous solid dispersions. J Pharm Sci. 2012;101:2798-810 pubmed publisher

Doumas M, Anyfanti P, Lazaridis N. Effects of antihypertensive therapy on female sexual dysfunction: clinically meaningful?. J Hypertens. 2012;30:1263-4; author reply 1264-5 pubmed publisher

Silverdal J, Mourtzinis G, Stener Victorin E, Mannheimer C, Manhem K. Antihypertensive effect of low-frequency transcutaneous electrical nerve stimulation (TENS) in comparison with drug treatment. Blood Press. 2012;21:306-10 pubmed

Zhang N, Yu L, Li J, Tong J, Meng J, Zhang Q, et al. [Analysis and evaluation of the impurity of felodipine and its tablets]. Yao Xue Xue Bao. 2012;47:223-8 pubmed

Blasko Markic M, Socan M. Tick-borne encephalitis in Slovenia: data from a questionnaire survey. Vector Borne Zoonotic Dis. 2012;12:496-502 pubmed publisher

Li H, Yin X, Ji J, Sun L, Shao Q, York P, et al. Microstructural investigation to the controlled release kinetics of monolith osmotic pump tablets via synchrotron radiation X-ray microtomography. Int J Pharm. 2012;427:270-5 pubmed publisher

Bhende S, Jadhav N. Moringa coagulant as a stabilizer for amorphous solids: Part I. AAPS PharmSciTech. 2012;13:400-10 pubmed publisher

Basalious E, El Sebaie W, El Gazayerly O. Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: development, optimization and in vitro/in vivo studies. Pharm Dev Technol. 2013;18:407-16 pubmed publisher

Hénin E, Bergstrand M, Standing J, Karlsson M. A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model. AAPS J. 2012;14:155-63 pubmed publisher

Bazzo G, Caetano D, Boch M, Mosca M, Branco L, Zétola M, et al. Enhancement of felodipine dissolution rate through its incorporation into Eudragit® E-PHB polymeric microparticles: in vitro characterization and investigation of absorption in rats. J Pharm Sci. 2012;101:1518-23 pubmed publisher

Ma R, Yu J, Xu D, Yang L, Lin X, Zhao F, et al. Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J Hypertens. 2012;30:210-6 pubmed publisher

Scoutaris N, Hook A, Gellert P, Roberts C, Alexander M, Scurr D. ToF-SIMS analysis of chemical heterogenities in inkjet micro-array printed drug/polymer formulations. J Mater Sci Mater Med. 2012;23:385-91 pubmed publisher

Hsiao C, Wu Y, Hsu K. Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. Arzneimittelforschung. 2011;61:444-51 pubmed

Schmidt M, Johansen M, Robertson D, Maeng M, Kaltoft A, Jensen L, et al. Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. Eur J Clin Invest. 2012;42:266-74 pubmed publisher

Scoutaris N, Alexander M, Gellert P, Roberts C. Inkjet printing as a novel medicine formulation technique. J Control Release. 2011;156:179-85 pubmed publisher

Basalious E, El Sebaie W, El Gazayerly O. Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a class II BCS drug using polymeric surfactants and crystallization inhibitors: development of controlled-release tablets. AAPS PharmSciTech. 2011;12:799-810 pubmed publisher

Zhang J, Bunker M, Parker A, Madden Smith C, Patel N, Roberts C. The stability of solid dispersions of felodipine in polyvinylpyrrolidone characterized by nanothermal analysis. Int J Pharm. 2011;414:210-7 pubmed publisher

Alonzo D, Gao Y, Zhou D, Mo H, Zhang G, Taylor L. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci. 2011;100:3316-3331 pubmed publisher

Qi S, Belton P, Nollenberger K, Gryczke A, Craig D. Compositional analysis of low quantities of phase separation in hot-melt-extruded solid dispersions: a combined atomic force microscopy, photothermal fourier-transform infrared microspectroscopy, and localised thermal analysis approach. Pharm Res. 2011;28:2311-26 pubmed publisher

Uesawa Y, Takeuchi T, Mohri K. Publication bias on clinical studies of pharmacokinetic interactions between felodipine and grapefruit juice. Pharmazie. 2010;65:375-8 pubmed

Cvetkovic R, Plosker G. Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension. Drugs. 2005;65:1851-68 pubmed

Haria M, Plosker G, Markham A. Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension. Drugs. 2000;59:141-57 pubmed

Little W, Cheng C, Elvelin L, Nordlander M. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Cardiovasc Drugs Ther. 1995;9:657-63 pubmed

Walton T, Symes L. Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. Clin Pharm. 1993;12:261-75 pubmed

Gradman A. Treatment of hypertension with felodipine in patients with concomitant diseases. Clin Cardiol. 1993;16:294-301 pubmed

Purcell H, Coats A. Structural changes in hypertension, the potential for their prevention, arrest and reversal: a focus on felodipine. Br J Clin Pract. 1994;48:311-6 pubmed

Gradman A. The evolving role of calcium channel blockers in the treatment of angina pectoris: focus on felodipine. Can J Cardiol. 1995;11 Suppl B:14B-21B pubmed

Dahlof B, Andersson O. A felodipine-metoprolol extended-release tablet: its properties and clinical development. J Hum Hypertens. 1995;9 Suppl 2:S43-7 pubmed

Trenkwalder P, Elmfeldt D. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs--the rationale and benefits of combining felodipine and metoprolol. J Hum Hypertens. 1995;9 Suppl 2:S37-42 pubmed

Dunselman P, Edgar B. Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991;21:418-30 pubmed

Yedinak K, Lopez L. Felodipine: a new dihydropyridine calcium-channel antagonist. DICP. 1991;25:1193-206 pubmed

Lorimer A, Pringle S. The safety of felodipine. J Cardiovasc Pharmacol. 1990;15 Suppl 4:S85-9 pubmed

Morgan T. A review of the antihypertensive effects of felodipine alone or in combination. J Cardiovasc Pharmacol. 1990;15 Suppl 4:S76-84 pubmed

Reid J. Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review. J Cardiovasc Pharmacol. 1990;15 Suppl 4:S50-6 pubmed

Lund Johansen P. Hemodynamic effects of felodipine in hypertension: a review. J Cardiovasc Pharmacol. 1990;15 Suppl 4:S34-9 pubmed

Elmfeldt D, Nordlander M, Edgar B. Renal effects of felodipine--a review. Kidney Int Suppl. 1992;36:S54-60 pubmed

DeQuattro V. Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients. Clin Exp Hypertens A. 1992;14:965-87 pubmed

Faulds D, Sorkin E. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients. Drugs Aging. 1992;2:374-88 pubmed

Todd P, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992;44:251-77 pubmed